Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Issue 3 (1st September 2013)
- Record Type:
- Journal Article
- Title:
- Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation. Issue 3 (1st September 2013)
- Main Title:
- Antiretroviral Solid Drug Nanoparticles with Enhanced Oral Bioavailability: Production, Characterization, and In Vitro–In Vivo Correlation
- Authors:
- McDonald, Tom O.
Giardiello, Marco
Martin, Philip
Siccardi, Marco
Liptrott, Neill J.
Smith, Darren
Roberts, Phill
Curley, Paul
Schipani, Alessandro
Khoo, Saye H.
Long, James
Foster, Alison J.
Rannard, Steven P.
Owen, Andrew - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Nanomedicine strategies have produced many commercial products. However, no orally dosed HIV nanomedicines are available clinically to patients. Although nanosuspensions of drug particles have demonstrated many benefits, experimentally achieving >25 wt% of drug relative to stabilizers is highly challenging. In this study, the emulsion‐templated freeze‐drying technique for nanoparticles formation is applied for the first time to optimize a nanodispersion of the leading non‐nucleoside reverse transcriptase inhibitor efavirenz, using clinically acceptable polymers and surfactants. Dry monoliths containing solid drug nanoparticles with extremely high drug loading (70 wt% relative to polymer and surfactant stabilizers) are stable for several months and reconstitute in aqueous media to provide nanodispersions with <italic>z</italic>‐average diameters of 300 nm. The solid drug nanoparticles exhibit reduced cytoxicity and increased in vitro transport through model gut epithelium. In vivo studies confirm bioavailability benefits with an approximately four‐fold higher pharmacokinetic exposure after oral administration to rodents, and predictive modeling suggests dose reduction with the new formulation may be possible.</p> </abstract>
- Is Part Of:
- Advanced healthcare materials. Volume 3:Issue 3(2014:Mar.)
- Journal:
- Advanced healthcare materials
- Issue:
- Volume 3:Issue 3(2014:Mar.)
- Issue Display:
- Volume 3, Issue 3 (2014)
- Year:
- 2014
- Volume:
- 3
- Issue:
- 3
- Issue Sort Value:
- 2014-0003-0003-0000
- Page Start:
- 400
- Page End:
- 411
- Publication Date:
- 2013-09-01
- Subjects:
- Biomedical materials -- Periodicals
610.28 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2192-2659 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/adhm.201300280 ↗
- Languages:
- English
- ISSNs:
- 2192-2640
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0696.854650
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3601.xml